(UroToday.com) The POUT trial (CRUK/11/027; NCT01993979) previously reported that adjuvant chemotherapy improves disease free survival (HR 0.45, 95% CI 0.30-0.68) for patients with histologically confirmed pT2-T4 N0-3 M0 upper tract urothelial carcinoma over a median follow-up of 30.3 months.1 At the GU ASCO 2021 annual meeting Dr. Alison Birtle and colleagues presented results of a pre-planned analysis updating the primary endpoint of disease free survival and reporting key secondary endpoints including overall survival.